Slideset
View More
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270
Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/
Downloadable slides on treatment strategies for CLL including the most recent data on BTK inhibitors, BCL-2 inhibitor, PI3K inhibitors, and CAR T-cell therapy.
John M. Burke, MD
Nicole Lamanna, MD
Released: June 19, 2019
Results from a phase II trial of ibrutinib, lenalidomide, and rituximab in non-GCB DLBCL as reported by CCO from ASCO 2019
Downloadable patient resource on CLL including helpful web sites containing treatment information and supportive care, as well as questions to ask your doctor during office visits
John M. Burke, MD
Nicole Lamanna, MD
Released: June 10, 2019
Phase III CLL14 trial of venetoclax plus obinutuzumab in previously untreated patients with CLL and comorbidities as reported by CCO from ASCO 2019
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.